An open organoid bank for cancers too rare to have models
For many rare cancers there is not a single laboratory model in the world, so no one can test drugs. A shared bank with free distribution would change that.
Rare and paediatric cancers lack cell lines and xenografts, which blocks even basic drug testing. A distributed programme would fund collection at referral centres, derive organoids and xenografts under a common protocol, characterise them genomically, and distribute them at cost with no reach-through rights. Precedents include the Human Cancer Models Initiative and paediatric preclinical testing programmes.
- Preclinical models that do not predict people · Nine in ten cancer drugs that work in mice fail in humans. Our models are the reason.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaAn open model bank for the rare tumours nobody has models for
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people, Biliary tract cancer (cholangiocarcinoma).
- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, National Cancer Institute (NIH), Sarcomas (soft tissue, bone, GIST).
- IdeaPick the laboratory model that matches the patient, not the one to hand
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people, National Cancer Institute (NIH).
- IdeaTest drugs on the patient's own cancer cells when there is no trial to join
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people, Biliary tract cancer (cholangiocarcinoma).
- IdeaBuild laboratory models of the organs cancer spreads to
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaBarcode patient-derived tumours to watch which clones win under each drug
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaGrow models from tumour cells in the blood when a biopsy is impossible
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaMulti-centre randomised animal trials before committing to a human trial
Shares Patient-derived xenografts, Preclinical models that do not predict people, National Cancer Institute (NIH).